Jiangsu Hengrui Pharmaceuticals (01276): HRS-7525 tablets obtained drug clinical trial approval notification.

21:21 16/06/2026

Hengrui Medicine (01276) announces that recently, Jiangsu Hengrui Medicine Co., Ltd. (hereinafter referred to as the "Company") has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (hereinafter referred to as the "NMPA") for HRS-7525 tablets, and will conduct clinical trials in the near future.

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereinafter referred to as "the Company") has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (referred to as "NMPA"), and will soon begin clinical trials for HRS-7525 tablets. HRS-7525 tablets are innovative anti-tumor drugs independently developed by the Company, intended for the treatment of solid tumor patients. As of now, there are no similar products approved for marketing in China. Up to now, the accumulated research and development investment in the HRS-7525 tablet project is approximately 24.6 million yuan (unaudited).

IMMUNEONCO-B (01541) spent HK$592,500 to repurchase 163,200 shares on June 16.

Hubei Heyuan Gas Co., Ltd. (002971.SZ): Qian Tu privately reduces holdings to below 5%, planning to continue reducing holdings by no more than 1% of the shares.

Jiangsu Hengrui Pharmaceuticals' independently developed CDK4/6 inhibitor hydroxyethyl sulfonate dalsalic tablets has received approval for new indications by the National Medical Products Administration.

IMMUNEONCO-B (01541) spent HK$592,500 to repurchase 163,200 shares on June 16.

Hubei Heyuan Gas Co., Ltd. (002971.SZ): Qian Tu privately reduces holdings to below 5%, planning to continue reducing holdings by no more than 1% of the shares.